What's in Lars Kristian Munck's pipeline?

Lars Kristian Munck has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Lars Kristian Munck's portfolio?

Top competitors by shared drug class: Mirum Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lars-kristian-munck.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Lars Kristian Munck — Portfolio Competitive Intelligence Brief

Lars Kristian Munck pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Oral chenodeoxycholic acid stimulation	Oral chenodeoxycholic acid stimulation	marketed	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5	Hepatology / Gastroenterology

Therapeutic area mix

Hepatology / Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Mirum Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lars Kristian Munck:

Cite this brief

Drug Landscape (2026). Lars Kristian Munck — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lars-kristian-munck. Accessed 2026-05-16.